"
Team:Imperial College London
From 2009.igem.org
JamesField (Talk | contribs) |
|||
| Line 3: | Line 3: | ||
For iGEM 2009 the Imperial College London team present you with <i>The E.ncapsulator</i>; a versatile manufacture and delivery platform by which therapeutics can be reliably targeted to the intestine. | For iGEM 2009 the Imperial College London team present you with <i>The E.ncapsulator</i>; a versatile manufacture and delivery platform by which therapeutics can be reliably targeted to the intestine. | ||
| - | Our E.coli chassis progresses through a series of defined stages culminating in the production of a safe, inanimate pill. This sequential process involves drug production, | + | Our <i>E.coli</i> chassis progresses through a series of defined stages culminating in the production of a safe, inanimate pill. This sequential process involves drug production, protective encapsulation and genome deletion. The temporal transition between each of these stages is coordinated by both chemical and physical cues. |
<i>The E.ncapsulator</i> provides an innovative method to deliver any biologically synthesisable compound and bypasses the need for expensive storage, packaging and purification processes. <i>The E.ncapsulator</i> is an attractive candidate for commercial pill development and demonstrates the massive manufacturing potential in Synthetic Biology. | <i>The E.ncapsulator</i> provides an innovative method to deliver any biologically synthesisable compound and bypasses the need for expensive storage, packaging and purification processes. <i>The E.ncapsulator</i> is an attractive candidate for commercial pill development and demonstrates the massive manufacturing potential in Synthetic Biology. | ||
Revision as of 09:55, 24 September 2009
For iGEM 2009 the Imperial College London team present you with The E.ncapsulator; a versatile manufacture and delivery platform by which therapeutics can be reliably targeted to the intestine.
Our E.coli chassis progresses through a series of defined stages culminating in the production of a safe, inanimate pill. This sequential process involves drug production, protective encapsulation and genome deletion. The temporal transition between each of these stages is coordinated by both chemical and physical cues.
The E.ncapsulator provides an innovative method to deliver any biologically synthesisable compound and bypasses the need for expensive storage, packaging and purification processes. The E.ncapsulator is an attractive candidate for commercial pill development and demonstrates the massive manufacturing potential in Synthetic Biology.
